Obsessive-compulsive disorder affects an estimated 2.3% of U.S. adults over a lifetime, and many people continue to experience significant symptoms even after first-line treatments such as serotonin reuptake inhibitors and cognitive-behavioral therapy with exposure and response prevention (National Institute of Mental Health, n.d.; International OCD Foundation, n.d.). If you have been through multiple treatment attempts and still find yourself caught in cycles of intrusive thoughts and compulsive rituals, that experience is real, valid, and increasingly understood by researchers exploring new intervention pathways. At Allevate Health in Princeton, NJ, our team offers IV ketamine therapy as a medically supervised option for individuals with treatment-resistant OCD.
Understanding Why OCD Can Be So Resistant to Treatment
OCD is far more than a habit disorder — it is a condition characterized by deeply entrenched neural circuits that drive intrusive thoughts and repetitive behaviors despite a person’s awareness that the thoughts are irrational. The standard of care combines selective serotonin reuptake inhibitors (SSRIs) with exposure and response prevention (ERP) therapy, but meaningful response rates leave a substantial portion of patients without adequate relief (Fineberg et al., 2012; International OCD Foundation, n.d.). Challenges that contribute to treatment resistance in OCD include:
Partial responders: Many patients achieve some reduction in symptoms but continue to experience significant functional impairment.
Side effect burden: High SSRI doses often required for OCD can be poorly tolerated.
ERP accessibility: Effective ERP requires significant time commitment and access to specialized therapists, which can be a barrier in many communities.
Augmentation complexity: Adding a second agent often yields modest additional benefit and introduces more side effect risk.
These realities can feel discouraging, particularly when you have invested time, energy, and hope into treatments that have not delivered the relief you hoped for. One barrier to pursuing novel treatments is uncertainty about the evidence base — understanding what the research actually shows is an important first step. Discussing your full treatment history with your provider before beginning anything new remains essential.
Ketamine’s Mechanism and Its Relevance to OCD
The predominant theory linking ketamine to OCD symptom relief centers on the glutamate neurotransmitter system. Research implicates dysregulation of glutamatergic transmission in the cortico-striato-thalamo-cortical (CSTC) circuits that underlie OCD symptomatology (Pittenger et al., 2011). Ketamine’s primary mechanism — blocking the NMDA glutamate receptor — is thought to rapidly recalibrate signaling in these overactive circuits.
Beyond the NMDA receptor, ketamine triggers a cascade that includes increased BDNF (brain-derived neurotrophic factor) release and downstream activation of pathways involved in synaptic plasticity. This may allow the brain to form new neural pathways that are not bound by the deeply ingrained patterns that drive OCD. For a broader look at how different ketamine-based approaches are used in clinical care, see our overview of ketamine methods. Ketamine for OCD is an off-label use. While the neurobiological rationale is compelling, results vary by individual, and the evidence base continues to evolve. This treatment is best understood as a complement to — not a replacement for — ongoing behavioral or pharmacological care.
What the Research Shows
A randomized controlled crossover trial by Rodriguez et al. (2013) found that a single IV infusion of ketamine produced rapid, significant reductions in obsessive-compulsive symptoms in individuals with near-constant intrusive obsessions, with some participants experiencing meaningful relief within hours of infusion. The study demonstrated effects that persisted for days after a single dose, which was notable given the typically slow-acting nature of conventional OCD pharmacotherapy.
Subsequent research has explored the relationship between ketamine’s glutamate-mediated effects and the specific OCD symptom dimensions most likely to respond (Rodriguez et al., 2016). Preliminary evidence suggests that individuals with more prominent intrusive thought clusters may experience more noticeable short-term effects, though the field has not yet established reliable predictors of response. Larger controlled trials are still needed, and the literature should be interpreted with appropriate caution — this is promising but still-developing science. Results vary by individual, and discuss with your provider whether the existing evidence base supports pursuing this approach in your particular situation. For more on the science underlying these effects, our post on the science of ketamine for OCD relief provides additional context.
IV Ketamine Therapy at Allevate Health Princeton
At our Princeton, NJ location at 707 State Road Suite 105, IV ketamine infusions are delivered in a calm, medically supervised setting. Patients considering treatment for OCD go through the same careful intake process as those seeking treatment for depression or other conditions. Key components of the treatment process:
Complimentary consultation: Our team reviews your OCD diagnosis, symptom profile, prior treatment history (medications, therapy, augmentation attempts), and current medications.
Personalized protocol: Because OCD treatment protocols may differ somewhat from depression protocols, dosing and session structure are individualized.
In-session monitoring: You are comfortably situated and monitored throughout each 40–60-minute infusion, with staff present the entire time.
Coordinated care: We actively encourage coordination with your existing psychiatrist or OCD therapist so that ketamine can be integrated into your broader care plan.
Follow-up planning: Our team discusses response and next steps after the initial treatment plan is complete.
A second common barrier is concern about experiencing dissociative effects during an infusion. Ketamine can produce altered perceptual states at treatment doses — our team explains what to expect beforehand and supports you through the experience in a safe, structured environment.
Who May Be a Candidate
IV ketamine therapy at our Princeton, NJ location may be worth exploring if you have a confirmed OCD diagnosis, have completed adequate trials of SSRI-based regimens and ERP therapy without sufficient relief, and do not have contraindications such as active psychosis, uncontrolled hypertension, or substance use concerns. Our guide to preparing for a ketamine therapy consultation provides additional information about what to bring and what questions to ask. You may also wish to review SPRAVATO® treatment as an FDA-approved option for treatment-resistant depression and certain related mood presentations. To schedule a complimentary consultation, contact Allevate Health or call our Princeton location at 640-252-9785.
Frequently Asked Questions
Q: Is ketamine approved by the FDA for OCD?
A: No. IV ketamine for OCD is an off-label application. Ketamine injection is FDA-approved as an anesthetic, while OCD is not an FDA-approved indication for ketamine (DailyMed, 2026). The FDA has approved SPRAVATO® (esketamine nasal spray) for treatment-resistant depression and depressive symptoms in adults with MDD with acute suicidal ideation or behavior, but ketamine-based treatments for OCD are used based on clinical evidence and physician judgment outside of formal FDA-approved indications (U.S. Food and Drug Administration, 2025).
Q: How quickly might I notice a change in OCD symptoms after a ketamine infusion?
A: Some patients in research studies noticed reductions in obsessive-compulsive symptoms within hours of a single infusion (Rodriguez et al., 2013). However, individual responses vary significantly. Your provider can help you understand what would count as a meaningful response in your specific case.
Q: Can I continue my current OCD medications while receiving IV ketamine?
A: In many cases, yes — but this depends on the specific medications involved. Some agents may interact with ketamine or influence its effectiveness. Our team reviews your full medication list during the consultation and advises accordingly.
Q: Does ketamine replace ERP therapy for OCD?
A: No. Ketamine is best understood as a potential adjunct or bridge treatment that may reduce symptom intensity enough to allow other therapies — including ERP — to become more accessible or effective. Our team encourages ongoing engagement with behavioral therapy alongside any biological treatment.
Q: Are there any OCD symptom types that respond better to ketamine?
A: Early research suggests variability in response across OCD symptom dimensions, with some evidence that intrusive thought-focused presentations may show more acute benefit. However, the evidence is preliminary and response prediction is not yet reliable at the individual level. A thorough consultation is the best way to assess whether this treatment is appropriate for you.
Key Takeaways
OCD affects an estimated 2.3% of U.S. adults over a lifetime, and many people continue to experience significant symptoms despite first-line treatment.
Ketamine’s mechanism — NMDA receptor blockade and glutamatergic modulation — targets neural systems implicated in OCD symptomatology.
Pilot and controlled research has demonstrated rapid reductions in OCD symptoms following a single IV ketamine infusion, with effects persisting for days in some participants.
IV ketamine for OCD is an off-label use; results vary by individual and should be pursued only as part of a comprehensive care plan supervised by a qualified provider.
Allevate Health in Princeton, NJ offers IV ketamine in a medically supervised setting, starting with a complimentary consultation.
References
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012). Evidence-based pharmacotherapy of obsessive-compulsive disorder. International Journal of Neuropsychopharmacology, 15(8), 1173–1191. https://doi.org/10.1017/S1461145711001829
International OCD Foundation. (n.d.). Medication. https://iocdf.org/about-ocd/ocd-treatment-guide/understanding-medication/
National Institute of Mental Health. (n.d.). Obsessive-compulsive disorder (OCD). https://www.nimh.nih.gov/health/statistics/obsessive-compulsive-disorder-ocd
Pittenger, C., Bloch, M. H., & Williams, K. (2011). Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics, 132(3), 314–332. https://doi.org/10.1016/j.pharmthera.2011.09.006
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., Simpson, H. B., & Liebowitz, M. R. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology, 38(12), 2475–2483. https://doi.org/10.1038/npp.2013.150
Rodriguez, C. I., Wheaton, M., Zwerling, J., Steinman, S. A., Sonnenfeld, D., Galfalvy, H., Simpson, H. B., & Foa, E. B. (2016). Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. Journal of Clinical Psychiatry, 77(3), 408–409. https://doi.org/10.4088/JCP.15l10138
U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray, CIII prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy and SPRAVATO® should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.